Cellectar Biosciences, Inc. (CLRB) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

8/25

Growth 2 Margin 1 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

8
Selectar Biosciences (CLRB) Q2 2026: Confirmatory Phase III Trial Initiation Signals Regulatory Acceleration
August 17, 2026
8
Selectar Biosciences (CLRB) Q1 2026: $140M Financing Unlocks Phase III WM Launch and Accelerated Approval Path
June 17, 2026
6
CLRB Q2 2025: $45M Confirmatory Study Cost Anchors Accelerated Approval Path for Lead Radiopharma
June 16, 2026
8
Selectar Biosciences (CLRB) Q3 2025: $12.7M Financing Extends Runway, Regulatory Milestones Accelerate Iopofacine Path
June 16, 2026
9
CLRB Q4 2025: R&D Spend Falls 57% as Regulatory Milestones Unlock Accelerated Approval Path
June 15, 2026
9
CLRB Q4 2025: R&D Spend Drops 57% as Regulatory Milestones Drive Pipeline Momentum
June 15, 2026
7
Cellectar Biosciences (CLRB) Q1 2025: 59% Major Response Rate Drives EMA Conditional Approval Pathway
May 13, 2025
7
Cellectar Biosciences (CLRB) Q4 2024: $30M Confirmatory Study Sets Clear FDA Path for Iopofosine in Waldenström Macroglobulinemia
March 13, 2025

Browse all companies